| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G |
| 16 Nov 2026 | 144 |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 | SCHEDULE 13G |
| 03 Nov 2026 |
8-K: Regulation FD Disclosure; Other Events
WARREN, N.J., Nov. 3, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of the Company’s outstanding shar... |
| 29 Oct 2026 | 10-Q |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
– Strong Q3 2026 performance with total revenue of $358 million, including $276 million of product revenue – |
| 16 Oct 2026 |
Form 4: Schmertzler Michael, Director
Sold 2,500 shares ($149K) |
| 13 Oct 2026 |
Form 4: Boulding Mark Elliott, EXEC. VP AND CLO
Received 192 shares by exercise or conversion ($7.57K) · Sold 192 shares ($12.3K) |
| 09 Oct 2026 |
Form 4: Schmertzler Michael, Director
Sold 2,500 shares ($158K) |
| 09 Oct 2026 | 144 |
| 07 Oct 2026 |
Form 4: Boulding Mark Elliott, EXEC. VP AND CLO
Received 1,638 shares by exercise or conversion ($64.6K) · Sold 1,638 shares ($105K) · Received 435 shares by exercise or conversion ($17.1K) · 1 more |
| 07 Oct 2026 | 144 |
| 06 Oct 2026 | 144 |
| 05 Oct 2026 | 144 |
| 02 Oct 2026 |
Form 4: Steele Glenn Jr Md Phd, Director
Received 12,000 shares by exercise or conversion ($135K) · Sold 12,000 shares ($782K) |
| 30 Sep 2026 | 144 |
| 21 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
WARREN, N.J., Sept. 21, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it completed the previously announced agreement with Sangamo Therapeutics, Inc. to acquire ST-920 – a BLA-stage, one-time administered AAV gene th... |
| 18 Sep 2026 |
Form 4: Schmertzler Michael, Director
Sold 10,000 shares ($671K) · Sold 10,000 shares ($679K) |
| 11 Sep 2026 |
Form 4: Schmertzler Michael, Director
Sold 10,000 shares ($678K) · Sold 10,000 shares ($673K) |
Loading...